SCHEMBL698616

SCHEMBL698616

O=[PH](O)OCc1ccccc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.48
ALDH1A1 P00352 4/20 0.47
SLC6A2 P23975 2/20 0.45
SLC6A3 Q01959 2/20 0.45
L3MBTL1 Q9Y468 2/20 0.45
MAPK1 P28482 1/20 0.45
KMT2A Q03164 1/20 0.45
TDP1 Q9NUW8 1/20 0.45
IDO1 P14902 1/20 0.44
AGXT P21549 1/20 0.43
LMNA P02545 2/20 0.42
CA1 P00915 2/20 0.42
CA2 P00918 2/20 0.42
CA9 Q16790 2/20 0.42
CYP1A2 P05177 1/20 0.42
PTGS1 P23219 1/20 0.42
CYP2C19 P33261 1/20 0.42
PTGS2 P35354 1/20 0.42
HIF1A Q16665 1/20 0.42
HDAC6 Q9UBN7 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL7385052 0.98 AGXT (0.46) TSHRALDH1A1SLC6A2SLC6A3L3MBTL1
SCHEMBL15961256 0.98 TSHR (0.46) TSHRALDH1A1SLC6A2SLC6A3L3MBTL1
Ethylene Glycol SCHEMBL28921702 0.94 TSHR (0.43) TSHRALDH1A1SLC6A2SLC6A3L3MBTL1
SCHEMBL29035063 0.92 TSHR (0.41) TSHRALDH1A1SLC6A2SLC6A3L3MBTL1
Butane SCHEMBL1238313 0.92 ALDH1A1 (0.46) TSHRALDH1A1SLC6A2SLC6A3L3MBTL1
SCHEMBL20589969 0.90 ALDH1A1 (0.44) TSHRALDH1A1SLC6A2SLC6A3L3MBTL1
Aniline SCHEMBL29187471 0.89 MAOB (0.50) TSHRALDH1A1L3MBTL1IDO1AGXT
Aniline SCHEMBL29187472 0.89 MAOB (0.50) TSHRALDH1A1L3MBTL1IDO1AGXT
SCHEMBL29255545 0.87 PTGS1 (0.59) SLC6A2SLC6A3L3MBTL1LMNACYP1A2
Di(Hydroxyethyl)Ether SCHEMBL28629273 0.87 TSHR (0.42) TSHRALDH1A1SLC6A2SLC6A3L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 533 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024105686-A1 A PROCESS FOR THE SYNTHESIS OF STILBENE AND INTERMEDIATES THEREOF FERTIS INDIA PVT LTD (IN) 2024-05-23 WO claimed
EP-3107647-B1 PROCESS FOR FORMING DUST-FREE ADDITIVE GRANULES SI GROUP SWITZERLAND CHAA GMBH (CH) 2020-12-23 EP claimed
US-20180052952-A9 METHODS AND APPARATUS FOR DOUBLE-INTEGRATION ORTHOGONAL SPACE TEMPERING FLORIDA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) 2018-02-22 US claimed
US-20170014790-A1 Process ADDIVANT SWITZERLAND GMBH (CH) 2017-01-19 US claimed
EP-3107647-A2 PROCESS FOR FORMING DUST-FREE ADDITIVE GRANULES Addivant Switzerland GmbH (CH) 2016-12-28 EP claimed
CN-103172512-B A group of compounds with similar cajanin structure, preparation method and application 中国医学科学院医药生物技术研究所 2016-08-03 CN claimed
US-9310544-B2 Polarizer and display device including the same SAMSUNG DISPLAY CO., LTD. (KR) 2016-04-12 US claimed
US-20150226893-A1 POLARIZER, DISPLAY DEVICE INCLUDING THE SAME AND METHOD OF MANUFACTURING THE POLARIZER SAMSUNG DISPLAY CO., LTD. (KR) 2015-08-13 US claimed
US-20140371232-A1 CAJANINE STRUCTURE ANALOGOUS COMPOUND, PREPARATION METHOD AND USE INSTITUTE OF MEDICINAL BIOTECHNOLOGY, CHINESE ACADEMY OF MEDICAL SCIENCES (CN) 2014-12-18 US claimed
EP-2796442-A1 CAJANINE STRUCTURE ANALOGOUS COMPOUND, PREPARATION METHOD AND USE Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences (CN) 2014-10-29 EP claimed
EP-0206000-A1 (2,3)-Alpha-methylenepenam-3-carboxylic acids and derivatives thereof F. HOFFMANN-LA ROCHE AG (CH) 1986-12-30 EP claimed
EP-0187355-A1 Process for preparing beta-lactam antibiotics E.R. Squibb & Sons, Inc. (US) 1986-07-16 EP claimed
US-4533660-A Antibacterial O-sulfated β-lactam hydroxamic acids E. R. SQUIBB & SONS, INC. (US) 1985-08-06 US claimed
EP-0051381-B1 O-SULFATED BETA-LACTAM HYDROXAMIC ACIDS E.R. Squibb & Sons, Inc. (US) 1985-01-30 EP claimed
EP-0032586-B1 DURABLE POLYESTER MOLDING COMPOSITION GAF CORPORATION (US) 1984-01-11 EP claimed
EP-0051381-A1 O-sulfated beta-lactam hydroxamic acids E.R. Squibb & Sons, Inc. (US) 1982-05-12 EP claimed
EP-0048953-A2 Beta-lactam antibiotics E.R. Squibb & Sons, Inc. (US) 1982-04-07 EP claimed
EP-0032586-A2 Durable polyester molding composition GAF CORPORATION (US) 1981-07-29 EP claimed
US-4277391-A CONTAINING THREE DIFFERENT TYPES OF ANTIOXIDANTS GAF CORPORATION (US) 1981-07-07 US claimed
US-4250320-A Process for producing substituted benzoxaphospholes MONSANTO COMPANY (US) 1981-02-10 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140371232-A1 CAJANINE STRUCTURE ANALOGOUS COMPOUND, PREPARATION METHOD AND USE ACHE, GAP43, LNPK TSHR 4767/4885ALDH1A1 2762/4885SLC6A2 584/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.